DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Indoximod is an investigational drug.
There have been 14 clinical trials for Indoximod. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.
The most common disease conditions in clinical trials are Brain Neoplasms, Glioma, and Glioblastoma. The leading clinical trial sponsors are NewLink Genetics Corporation, National Cancer Institute (NCI), and Emory University.
There are fifty-six US patents protecting this investigational drug and four hundred and thirty-five international patents.
Recent Clinical Trials for Indoximod
|Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG||Emory University||Phase 2|
|Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG||Theodore S. Johnson||Phase 2|
|A 2-part, Phase 1, Randomized Study in Health Men to: 1) Evaluate the Pharmacokinetics and Safety of Different Doses Indoximod HCL (Salt) Tablets and; 2) Compare the Proportion of 2 Different Formulations of Indoximod That Enters the Circulation and||NewLink Genetics Corporation||Early Phase 1|
Top disease conditions for Indoximod
Top clinical trial sponsors for Indoximod
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Indoximod||See Pricing||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||See Pricing|
|Indoximod||See Pricing||Antibodies to ICOS||Jounce Therapeutics, Inc. (Cambridge, MA)||See Pricing|
|Indoximod||See Pricing||Tank-binding kinase inhibitor compounds||Gilead Sciences, Inc. (Foster City, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Indoximod||European Patent Office||1917020||2025-07-07||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|